Study guide
4.1 Mood Disorders: Major Depression & Bipolar Spectrum
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
4.1 Mood Disorders: Major Depression & Bipolar Spectrum
Key Takeaways Explain This Topic AI
Major Depressive Disorder (MDD) requires ≥5 of 9 SIGECAPS symptoms for ≥2 consecutive weeks, with at least one symptom being depressed mood or anhedonia.
Bipolar I disorder requires at least 1 manic episode lasting ≥7 days (or any duration if hospitalization is required), whereas Bipolar II requires ≥1 hypomanic episode (≥4 days) and ≥1 major depressive episode without prior mania.
Persistent Depressive Disorder (Dysthymia) is characterized by depressed mood for most of the day for at least 2 years in adults (1 year in children/adolescents) with no symptom-free period exceeding 2 months.
Electroconvulsive therapy (ECT) is indicated for severe depression with psychotic features, acute suicidality, catatonia, or severe treatment resistance, with a response rate of 70% to 90%.
Maintenance antidepressant therapy should be continued for 4–9 months after a single MDD episode, 1–3 years for recurrent episodes (≥2), and indefinitely for severe, highly recurrent, or chronic depression.
Last updated: July 2026
Clinical Overview & Epidemiology
Mood disorders represent a leading cause of disability worldwide. On the USMLE Step 2 CK, distinguishing unipolar depression from bipolar spectrum disorders is a critical clinical skill because inappropriate antidepressant monotherapy in bipolar illness can precipitate iatrogenic mania or rapid cycling. Mood disorders are classified based on the presence, duration, and severity of depressive, manic, or hypomanic episodes.
Diagnostic Criteria for Major Depressive Disorder (MDD)
To meet DSM-5 diagnostic criteria for Major Depressive Disorder , a patient must experience ≥5 of the 9 SIGECAPS symptoms during the same 2-week period , representing a clear change from previous functioning. At least one of the symptoms must be depressed mood or anhedonia (loss of interest or pleasure).
- S — S leep disturbances (insomnia or hypersomnia)
- I — I nterest loss (anhedonia)
- G — G uilt or feelings of worthlessness
- E — E nergy reduction or fatigue
- C — C oncentration impairment or indecisiveness
- A — A ppetite or weight changes (increase or decrease of >5% in a month)
- P — P sychomotor agitation or retardation (observable by others)
- S — S uicidal ideation, recurrent thoughts of death, or suicide attempts
Symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning and must not be attributable to the physiological effects of a substance or another medical condition (e.g., hypothyroidism).
Diagnostic & Screening Algorithm for Mood Disorders Diagnostic Flowchart for Depressed or Elevated Mood:
1. Assess duration and symptom core:
- Depressed mood/anhedonia + ≥5 total SIGECAPS symptoms for ≥2 weeks -> Evaluate for Major Depressive Disorder.
- Depressed mood for ≥2 years (never asymptomatic >2 months) + ≥2 symptoms -> Persistent Depressive Disorder (Dysthymia).
2. Screen for manic or hypomanic episodes:
- ≥1 manic episode (≥7 days or requiring hospitalization, causing severe impairment) -> Bipolar I Disorder.
- ≥1 hypomanic episode (≥4 days, no marked impairment, no psychosis) AND ≥1 MDD episode -> Bipolar II Disorder.
- Fluctuating hypomanic and depressive symptoms for ≥2 years without meeting full MDE or manic criteria -> Cyclothymic Disorder.
3. Rule out secondary etiologies:
- Medical conditions (e.g., hypothyroidism, Cushing syndrome, stroke, pancreatic carcinoma).
- Substance/medication-induced (e.g., beta-blockers, corticosteroids, interferon-alpha, alcohol/cocaine withdrawal).
Differential Diagnosis of Mood Spectrum Disorders
Accurate diagnosis hinges on identifying symptom duration, severity, and history of elevated mood.
Disorder Episode Duration Core Clinical Criteria Distinguishing Feature First-Line Management
Major Depressive Disorder (MDD) ≥2 consecutive weeks ≥5 of 9 SIGECAPS symptoms (must include depressed mood or anhedonia) Functional decline without manic/hypomanic history SSRI/SNRI + Psychotherapy (CBT)
Persistent Depressive Disorder (Dysthymia) ≥2 years (adults) / ≥1 year (kids) Chronic depressed mood + ≥2 secondary depressive symptoms No symptom-free interval >2 months SSRI/SNRI + Psychotherapy
Bipolar I Disorder Manic: ≥7 days (or any if hospitalized) ≥1 manic episode ( DIG FAST criteria) ± major depressive episodes Mania induces severe social/occupational ruin or psychosis Lithium, Valproate, or SGAs (e.g., Quetiapine)
Bipolar II Disorder Hypomanic: ≥4 days; MDE: ≥14 days ≥1 hypomanic episode AND ≥1 major depressive episode Never has full manic episode or psychosis during hypomania Quetiapine, Lurasidone, Lithium
Cyclothymic Disorder ≥2 years chronic fluctuation Hypomanic & depressive periods that do not meet full episode criteria Mild chronic mood instability without full MDE or mania Mood stabilizers (Valproate, Lithium) / CBT
The DIG FAST mnemonic identifies manic and hypomanic symptoms: D istractibility, I ndiscretion/impulsivity, G randiosity, F light of ideas/racing thoughts, A ctivity increase (goal-directed), S leep requirement decrease (e.g., feeling rested after 2 hours), and T alkativeness (pressured speech).
- Psychopharmacology & Somatic Interventions
- Antidepressant Classes & Adverse Effect Profiles
Selective Serotonin Reuptake Inhibitors (SSRIs) (e.g., Escitalopram, Fluoxetine, Sertraline): First-line for MDD and anxiety disorders. Common side effects include sexual dysfunction, gastrointestinal distress, weight changes, and emotional blunting. Fluoxetine has the longest half-life (~1–2 weeks for active metabolite norfluoxetine).
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (e.g., Venlafaxine, Duloxetine): First-line alternative, especially in patients with comorbid neuropathic pain or fibromyalgia. Venlafaxine can cause dose-dependent hypertension due to noradrenergic stimulation.
Atypical Antidepressants :
Bupropion : Norepinephrine-dopamine reuptake inhibitor. Does not cause sexual dysfunction or weight gain. Contraindicated in patients with bulimia nervosa, anorexia nervosa, or seizure disorders due to a lowered seizure threshold.
Mirtazapine : Alpha-2 antagonist and 5-HT2/5-HT3 receptor antagonist. Promotes sedation and weight gain/appetite stimulation , making it ideal for elderly patients with depression, severe insomnia, and cachexia.
Tricyclic Antidepressants (TCAs) (e.g., Amitriptyline, Nortriptyline): Inhibits 5-HT and NE reuptake; blocks H1, alpha-1, and muscarinic receptors. Toxic in overdose due to the 3 Cs : C ardiotoxicity (wide QRS complex, arrhythmias due to fast sodium channel blockade), C onvulsions (seizures), and C oma. Treatment for TCA-induced sodium channel blockade is intravenous sodium bicarbonate .
Monoamine Oxidase Inhibitors (MAOIs) (e.g., Phenelzine, Tranylcypromine, Selegiline): Reserved for refractory depression. Risk of hypertensive crisis when combined with tyramine-rich foods (aged cheeses, wine, cured meats) due to uninhibited accumulation of sympathomimetic amines.
Mood Stabilizers in Bipolar Disorder
Lithium : Reduces suicide risk in bipolar disorder. Excreted renally. Toxicity presents with coarse tremor, ataxia, confusion, and emesis. Chronic side effects include nephrogenic diabetes insipidus , hypothyroidism , epstein anomaly (if taken in 1st trimester of pregnancy), and tubulointerstitial nephritis. Mandatory lab monitoring: TSH, BUN/Creatinine, serum lithium levels, and calcium.
Valproic Acid / Divalproex : Preferred for rapid cycling bipolar disorder (>4 episodes/year). Side effects include hepatotoxicity, pancreatitis, thrombocytopenia, and neural tube defects (spina bifida).
Lamotrigine : Effective for bipolar depression maintenance. Requires slow titration due to risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Somatic Therapies: Electroconvulsive Therapy (ECT)
ECT is the most rapidly effective treatment for major depression, with a response rate exceeding 80%. Absolute indications include:
- Severe depression with psychotic features
- Acute suicidality requiring rapid response
- Depression causing severe catatonia or refusal to eat/drink leading to dehydration
- Treatment-resistant depression failing multiple drug trials
- Pregnancy where pharmacotherapy is contraindicated
The primary adverse effect is transient retrograde and anterograde amnesia , which typically resolves within a few months.
Treatment Duration & Maintenance Guidelines
Single MDD Episode : Continue antidepressant therapy for 4 to 9 months at the dose that achieved remission (continuation phase).
Recurrent MDD (≥2 episodes), severe episodes (suicide attempt), or chronic duration (≥2 years) : Maintain antidepressant therapy for 1 to 3 years or indefinitely .
Discontinuation of SSRIs/SNRIs (especially Paroxetine or Venlafaxine) requires gradual tapering over weeks to prevent SSRI discontinuation syndrome (flu-like symptoms, electric-shock sensations, dizziness, anxiety).